GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » Operating Margin %

IXICO (LSE:IXI) Operating Margin % : -17.53% (As of Sep. 2024)


View and export this data going back to 1996. Start your Free Trial

What is IXICO Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. IXICO's Operating Income for the six months ended in Sep. 2024 was £-0.57 Mil. IXICO's Revenue for the six months ended in Sep. 2024 was £3.23 Mil. Therefore, IXICO's Operating Margin % for the quarter that ended in Sep. 2024 was -17.53%.

The historical rank and industry rank for IXICO's Operating Margin % or its related term are showing as below:

LSE:IXI' s Operating Margin % Range Over the Past 10 Years
Min: -72.52   Med: -18.07   Max: 11.89
Current: -37.36


LSE:IXI's Operating Margin % is ranked better than
64.79% of 1011 companies
in the Biotechnology industry
Industry Median: -162.31 vs LSE:IXI: -37.36

IXICO's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

IXICO's Operating Income for the six months ended in Sep. 2024 was £-0.57 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was £-2.15 Mil.


IXICO Operating Margin % Historical Data

The historical data trend for IXICO's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO Operating Margin % Chart

IXICO Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.83 11.89 10.51 -21.56 -37.36

IXICO Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.65 -28.50 -15.14 -62.57 -17.53

Competitive Comparison of IXICO's Operating Margin %

For the Biotechnology subindustry, IXICO's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IXICO's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IXICO's Operating Margin % distribution charts can be found below:

* The bar in red indicates where IXICO's Operating Margin % falls into.



IXICO Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

IXICO's Operating Margin % for the fiscal year that ended in Sep. 2024 is calculated as

Operating Margin %=Operating Income (A: Sep. 2024 ) / Revenue (A: Sep. 2024 )
=-2.154 / 5.766
=-37.36 %

IXICO's Operating Margin % for the quarter that ended in Sep. 2024 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=-0.566 / 3.228
=-17.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IXICO  (LSE:IXI) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


IXICO Operating Margin % Related Terms

Thank you for viewing the detailed overview of IXICO's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


IXICO Business Description

Traded in Other Exchanges
Address
15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN
IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO Headlines

No Headlines